Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.29 AUD -6.45% Market Closed
Market Cap: 76m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one RCE stock under the Base Case scenario is 0.04 AUD. Compared to the current market price of 0.29 AUD, Recce Pharmaceuticals Ltd is Overvalued by 85%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RCE Relative Value
Base Case
0.04 AUD
Overvaluation 85%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.7
P/S
P/S
Price to Sales
7.7
vs History
96
vs Industry
16
Median 3Y
25.7
Median 5Y
54.7
Industry
2.5
Forward
7.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-15.5
Industry
21.2
Forward
-4.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
17
Median 3Y
-19.8
Median 5Y
-32.6
Industry
16.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
13
Median 3Y
-11.9
Median 5Y
-20.5
Industry
23.8
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
0
Median 3Y
13.1
Median 5Y
13.1
Industry
2.1
More Details
7.5
EV/S
EV/S
Enterprise Value to Sales
7.5
vs History
96
vs Industry
15
Median 3Y
25.4
Median 5Y
52.5
Industry
2.6
Forward
7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-14.5
Industry
12.5
Forward
-5.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-14.5
Industry
15.9
Forward
-4.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
19
Median 3Y
-18.5
Median 5Y
-30.2
Industry
14.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
17
Median 3Y
-18.4
Median 5Y
-29.9
Industry
17.2
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
0
Median 3Y
-51.1
Median 5Y
390.3
Industry
1.8
More Details

Multiples Across Competitors

RCE Competitors Multiples
Recce Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Recce Pharmaceuticals Ltd
ASX:RCE
76m AUD 7.7 -4.2 -4.5 -4.5
US
Eli Lilly and Co
NYSE:LLY
734.9B USD 15 66.2 35.6 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
366.6B USD 4.1 16.8 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.9 13.1 15
CH
Roche Holding AG
SIX:ROG
207.2B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
187.7B CHF 4.4 18.3 10.8 14.4
UK
AstraZeneca PLC
LSE:AZN
158.1B GBP 3.9 27.9 130.7 197
US
Merck & Co Inc
NYSE:MRK
199B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
137.5B USD 2.2 17.4 7.5 10.5
P/E Multiple
Earnings Growth PEG
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average P/E: 25.2
Negative Multiple: -4.2 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.2
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.8
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.9
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.4
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBITDA: 433.5
Negative Multiple: -4.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBIT: 1 867.1
Negative Multiple: -4.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1.1

See Also

Summary
RCE intrinsic value, competitors valuation, and company profile.
DCF Valuation
RCE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RCE stock valuation using valuation multiples.
Wall Street Estimates
RCE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RCE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 264,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.